Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Amortizatization of Intangibles: 2019-2025

Historic Amortizatization of Intangibles for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $300,000.

  • Revolution Medicines' Amortizatization of Intangibles changed negligibly% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year decrease of 21.38%. This contributed to the annual value of $44.6 million for FY2024, which is 100.70% up from last year.
  • Per Revolution Medicines' latest filing, its Amortizatization of Intangibles stood at $300,000 for Q3 2025, which was down 0.00% from $300,000 recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Amortizatization of Intangibles ranged from a high of $15.2 million in Q1 2024 and a low of $300,000 during Q2 2021.
  • For the 3-year period, Revolution Medicines' Amortizatization of Intangibles averaged around $4.4 million, with its median value being $300,000 (2025).
  • Per our database at Business Quant, Revolution Medicines' Amortizatization of Intangibles skyrocketed by 630.37% in 2023 and then tumbled by 35.60% in 2025.
  • Over the past 5 years, Revolution Medicines' Amortizatization of Intangibles (Quarterly) stood at $979,000 in 2021, then grew by 20.74% to $1.2 million in 2022, then spiked by 630.37% to $8.6 million in 2023, then increased by 2.24% to $8.8 million in 2024, then remained steady at $300,000 in 2025.
  • Its last three reported values are $300,000 in Q3 2025, $300,000 for Q2 2025, and $9.8 million during Q1 2025.